Most hematopoietic malignancies are comprised of cells that are functionally heterogeneous, with only a subset being responsible for tumor maintenance. These cancer stem cells are so named because they possess qualities reminiscent of normal tissue stem cells including self-renewal, prolonged survival, and the ability to give rise to cells with more differentiated characteristics. Effort is now focused on identifying cancer stem cells in various hematopoietic malignancies, and defining the cells of origin such that the stepwise accumulation of genetic/epigenetic events necessary for cancer stem cell development can be delineated. A detailed understanding of these processes could lead to development of therapeutics that more effectively treat hematopoietic malignancies and potentially other cancers.
INTRODUCTION
Many adult tissues contain stem cells that are able to divide and retain all of their proliferative and developmental potential (self-renewal), whereas at the same time giving rise to all specialized cells necessary for regeneration (differentiation). The most well-characterized tissue-specific stem cells are hematopoietic stem cells. Detailed characterization of hematopoietic stem cells, committed hematopoietic progenitor cells, and differentiated blood cells sets the stage for understanding hematopoietic malignancies [1] , their cells of origin, and the characteristics of cancer stem cells. Indeed, the modern concept of human cancer stem cells initiates from studies in acute myelogenous leukemias (AMLs) [2] .
The cancer stem cell concept is based on the idea that tumors of a specific tissue often appear to ''attempt'' to recapitulate the cellular heterogeneity found in the tissues of origin, and thus there are cells in the tumor that are stem cell-like giving rise to the varied cell types. A fundamental test for this hypothesis is whether tumor cells can be separated into those that have the ability to regenerate the tumor, and those that do not possess this ability. This cellular hierarchy has been most clearly demonstrated in acute myelogenous leukemias where some AMLs possess cells with a unique immunophenotype that are able to initiate leukemias in immunodeficient mice, whereas most cells are unable to initiate leukemia development [2, 3] . Furthermore, the cells that initiate leukemias also give rise to cells that have lost tumor-initiating activity and thus recapitulate the cellular heterogeneity found in the original tumor. Demonstrating this type of functional hierarchy and cellular heterogeneity identifies the presence of a leukemia (or cancer) stem cell as they are presently defined.
CANCER STEM CELLS IN MYELOID MALIGNANCIES
The most detailed characterization of myeloid cell development and stem cell biology has been performed in murine systems, and has informed similar approaches using human cells. Normal hematopoietic stem cells contain self-renewal properties, which are lost as the cells commit to myeloid development, giving rise to committed progenitor cells that, although remaining multipotent, no longer possess long-term self-renewal properties ( Figure 1 ). Current studies suggest that human HSC reside in a population of cells that are CD34 1 /CD38 2 , and that CD34 1 /CD38 1 cells contain populations that are committed to specific myeloid fates. Initial studies that demonstrated the presence of AML stem cells delineated the cell surface immunophenotype as CD34 1 /CD38 2 , thus suggesting similarities between normal and AML stem cells [2, 3] . Further characterization has demonstrated that in many cases the AML stem cells also express antigens such as CD123 (IL3-R) that are not normally found on human HSC [4] . Also, experimental evidence suggests that AML stem cells may respond differently to specific small molecules (NFKB inhibitors and parthenolide), providing evidence that there may be differences between normal and AML stem cells that can be leveraged for therapeutic benefit [5] . Detailed studies of well-defined murine models of AML also demonstrate phenotypic differences between normal and AML stem cells, supporting the possibility that AML stem cells have phenotypic, and hopefully functional differences that can be manipulated to specifically target this population of cells. Studies in chronic myelogenous leukemias (CML) have also been informative as to the properties of human leukemia stem cells. It is widely held that the cancer stem cell in chronic phase CML is similar if not identical to the normal HSC. However, recent data suggest that the leukemia stem cell maintaining blast crisis is more consistent with committed hematopoietic progenitors [6] . Thus, it appears that the characteristics of the leukemia stem cell evolve as the leukemia transitions from chronic phase to blast crisis. Future studies using improved model systems and technologies will no doubt improve our understanding of the cellular heterogeneity of myeloid malignancies and hopefully focus our attention on the cells most important to eradicate in patients.
A related but distinct question is what cells are the cell of origin for leukemias and leukemia stem cells. As normal HSC possess indefinite self-renewal properties, and chronic phase CML is likely initiated from HSC, it is clear that normal HSC can give rise to myeloid leukemias. However, the question arises as to whether more committed myeloid cells can give rise to AML (Figure 1 ). It would appear, based on the studies in blast crises CML, that leukemia stem cells can possess an immunophenotype more consistent with committed myeloid cells; however, these leukemias likely progressed from an HSC that harbored the BCR-ABL oncogene. Can AML be directly initiated from a committed myeloid progenitor cell? Recent studies in murine models have demonstrated that leukemias can be initiated from common myeloid progenitors or granulocyte macrophage progenitors [7, 8] . However, only certain fusion oncogenes such as those involving the MLL gene on chromosome 11q23 possess this activity, whereas others such as BCR-ABL do not possesses this ability [9] . The fact that leukemia can be initiated from a cell that lacks intrinsic self-renewal provides an opportunity to determine the pathways responsible for these properties. Ongoing studies will determine if AML can be initiated from human myeloid progenitor cells, and most importantly if leukemias initiated from different cells of origin have different therapeutic outcomes.
CANCER STEM CELLS IN LYMPHOID MALIGNANCIES
Self-renewal capacity in most tissues is lost as cells progress through their normal stages of differentiation; for example, myeloid lineage blood cells beyond the level of hematopoietic stem cells no longer possess self-renewal capacity. A notable exception to differentiation-associated loss of self-renewal is the lymphoid system, where self-renewal capacity is preserved through the memory lymphocyte stage to maintain life-long immune memory [10, 11] . Somatic hypermutation serves as a marker for the stage of differentiation at which B cell malignancies arise. In general, the presence of somatic hypermutation identifies a tumor as having arisen in germinal center or postgerminal center B cells, whereas the absence of mutation identifies pregerminal center B cells. In contrast to myeloid Normal hematopoietic development proceeds from hematopoietic stem through fully differentiated blood cells. A number of cell fate decisions are made during development that give rise to committed hematopoietic progenitors such as common lymphoid progenitors (CLP), common myeloid progenitors (CMP), granulocyte macrophage progenitors (GMP), and megakaryocyte erythroid progenitors (MEP). The only normal cells with self-renewal potential are hematopoietic stem cells. Leukemia stem cells (LSC) arise from hematopoietic stem cells and potentially more committed progenitor cells, and the fully developed AML cells are comprised of a mixture of cells with a hierarchy somewhat similar to normal hematopoiesis. malignancies [2, 3, 12] but consonant with the lineage's preserved self-renewal capacity, immunoglobulin (Ig) mutation patterns suggest that B cell malignancies can arise from cells throughout the stages of B cell differentiation ( Figure 2 ).
Multiple myeloma (MM) has generally been considered a disease of malignant plasma cells, and indeed, many of clinical consequences of the disease result from the plasma cell bulk. However, normal plasma cells are terminally differentiated and lack self-renewal capacity. Moreover, it has been clear for over 30 years that only a minority of cells from mouse and human MM were clonogenic [13, 14] . Investigators called these rare clonogenic cells ''tumor stem cells'' [13, 14] . This Although not ''traditional'' stem cells in that they lack multilineage potential, memory B cells can be considered ''honorary'' stem cells-they are long-lived, self-renew, and differentiate into plasma cells to maintain long-term immune memory. A transforming event in memory B cells may be able to produce MM, HL, or CLL, depending on the degree of differentiation associated with the transforming event.
low clonogenic potential could be explained by either proliferative capacity exclusively restricted to a small subset of cancer cells, or alternatively all the cells within a cancer retaining the capacity to proliferate but only at a low rate. Insufficient tools available at the time precluded investigators from distinguishing which of these 2 possibilities explained the low clonogenicity of MM. Cells phenotypically resembling mature B cells and sharing Ig gene sequences and idiotype specificity with MM plasma cells have also been found in the marrow and blood of patients with MM [15] [16] [17] , but their role in the pathogenesis of the disease has been unclear. All these data suggest that MM might originate from self-renewing B cells, rather than plasma cells. In fact, it has recently been shown that MM plasma cells actually arise from a small population of self-renewing cancer stem cells that resemble memory B cells [18, 19] . Not only do these clonotypic B cells circulate in most patients but they also are resistant to many standard anti-MM agents, and thus appear to be responsible for most disease relapses.
Reed-Sternberg (RS) cells, the hallmark of Hodgkin lymphoma (HL), are the only blood cells other than plasma cells to occasionally express CD138 [20] . This has led to the hypothesis that RS cells represent aberrant plasma cell differentiation, supported by data showing that RS cells from HL cell lines expressed a transcriptional profile similar to normal and malignant plasma cells [21] . Thus, like plasma cells in MM, RS may not represent HL stem cells. We and others [22] found that HL cell lines include a small population of cells that lack the RS markers CD15 and CD30 present on the rest of the cells, while expressing markers consistent with a memory B cell phenotype [23] . Moreover, this small subpopulation of phenotypic memory B cells possessed all of the clonogenic capacity within the HL cell lines. We also found that most HL patients, including those with earlystage disease, harbor circulating memory B cells with the same clonal Ig gene rearrangement as the patients' RS cells [23] . These data suggest that these clonotypic memory B cells likely represent the HL stem cells. A transforming event in hematopoietic stem cells can produce several different malignancies, CML, myelodysplastic syndrome (MDS), AML, and probably even acute lymphocytic leuekemia, depending on the degree differentiation associated with the oncogenic hit. Similarly, a transforming event in memory B cells may be able to produce either MM or HL (Figure 3 ).
CONCLUSION
Recent studies have begun to characterize the functional heterogeneity of cells present in various tumors. A discrete subpopulation that has properties similar to normal tissue stem cells can be identified in many hematologic malignancies. Future trials in human hematopoietic malignancies should be focused on whether eradication of the so-called cancer stem cells is critical to a successful therapeutic strategy. If the clinical relevance of cancer stem cells is established, targeting their unique properties should provide opportunities to develop novel therapeutics.
